Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314737 | 0.82 | ACHE (0.35) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25822794 | 0.81 | ACHE (0.37) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20113001 | 0.81 | ACHE (0.41) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23080176 | 0.80 | ACHE (0.38) | ACHEFOLH1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18137885 | 0.80 | ACHE (0.40) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15706851 | 0.79 | FOLH1 (0.32) | FOLH1 | |
| SCHEMBL14950991 | 0.79 | FOLH1 (0.32) | FOLH1 | |
| SCHEMBL26346638 | 0.79 | GLP1R (0.40) | FOLH1 | |
| SCHEMBL14682786 | 0.79 | CA2 (0.37) | FOLH1 | |
| SCHEMBL16174189 | 0.78 | ACHE (0.42) | ACHEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137864-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2022076859-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076853-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021263026-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021050554-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020163532-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | Synthorx, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |